<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of the study was to evaluate the efficacy and safety of administered intravenously niferidil in doses 10, 20 and 30 mkg per kg in patients with persistent <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) and flutter (AFL) for pharmacological cardioversion </plain></SENT>
<SENT sid="1" pm="."><plain>The study included 30 patients (22 male) with persistent AF (n = 28) and AFL (n = 2) without structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart diseases</z:e> with median <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> duration 6.1 +/- 4.8 months (2 weeks to 24 months) </plain></SENT>
<SENT sid="2" pm="."><plain>Niferidil was administered as 3 bolus injections (10 mkg per kg each) performed with the interval of 15 minutes </plain></SENT>
<SENT sid="3" pm="."><plain>Antiarrhythmic efficacy of niferidil in dose of 10 mkg per kg was 60%, in dose of 20 mkg per kg it was 70%, and in dose of 30 mkg per kg reached 90% prespectively </plain></SENT>
<SENT sid="4" pm="."><plain>The part of the patients, in whom QTc prolongation exceeded potentionally dangerous value of 500 mc, was 22.2% (6 of 27) </plain></SENT>
<SENT sid="5" pm="."><plain>None of the patients developed proarrhythmic side effect as <z:hpo ids='HP_0001664'>torsade de pointes</z:hpo> </plain></SENT>
</text></document>